Jeremy A. Warren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeremy A. Warren has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
Alfredo M. Carbonell
16 shared publicationsWilliam S. Cobb
University of South Carolina School of Medicine-Greenville, Department of Surgery, Prisma Health Upstate, 905 Verdae Blvd Suite 202, Greenville, SC, 29607, USA
14 shared publicationsDawn Blackhurst
7 shared publicationsJoseph A. Ewing
Health Sciences Center, Prisma Health Upstate, Greenville, USA
7 shared publicationsA. M. Carbonell
University of South Carolina School of Medicine, Greenville, SC, USA
3 shared publicationsCaitlin Crosier
Prisma Health Department of Surgery, USA
3 shared publications
Latest Publications
- 28 October 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 263
Outcomes of ventral hernia repair in women of childbearing age
- 28 October 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 263
Outcomes of ventral hernia repair in women of childbearing age
- 3 August 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (10) , 8945-8952
Robotic extended-view totally extraperitoneal approach for ventral and incisional hernia repair: single-center experience with 2-year follow-up
- 3 August 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (10) , 8945-8952
Robotic extended-view totally extraperitoneal approach for ventral and incisional hernia repair: single-center experience with 2-year follow-up
- 28 August 2025
- Published by Springer Nature
- p. 467-478
Progressive Preoperative Pneumoperitoneum
- 26 December 2024
- Published by Springer Nature in Hernia
- Vol. 29 (1) , 1-9
Characterizing patterns of opioid prescribing after outpatient ventral hernia repair with mesh
Purpose Despite efforts to minimize opioid prescribing, outpatient ventral hernia repair (VHR) with mesh remains notoriously painful, often requiring postoperative opioid analgesia. Here, we aim to characterize patterns of opioid prescribing for the heterogenous group of patients and procedures that comprise mesh-based, outpatient VHR. Methods The Abdominal Core Health Quality Collaborative registry was queried for patients undergoing VHR with mesh who were discharged the same or next day between January 2019 to October 2023. Procedures were broadly classified by approach and mesh location: open, minimally-invasive with intraperitoneal mesh (MIP), and minimally-invasive with retromuscular or preperitoneal mesh (MRPP). Surgeon-reported opioid prescription quantity and patient-reported 30-day consumption data were reviewed. Results Of 2,795 patients who met inclusion criteria (46.1% open, 22.7% MIP, 31.2% MRPP), approximately 80% of patients consumed ≤ 10 tablets of opioid pain medication (open 87.7%, MIP 78.4%, MRPP 84.2%). For patients who were prescribed ≤ 10 tablets, the median number of unconsumed tablets was 5 (IQR 0–8). For patients who were prescribed > 10 tablets, the median number of unconsumed tablets was 10 or more (open 10 [IQR 2–16], MIP 10 [IQR 2–18], MRPP 12 [IQR 5–16]). The number of tablets consumed was positively correlated with the number of tablets prescribed (Kendall's rank correlation = 0.232, p < 0.001). Conclusion Regardless of technique, for outpatient VHR with mesh, the fewer opioid tablets prescribed, the fewer tablets patients consumed. Decreasing the prescription quantity to ≤ 10 tablets, coupled with preoperative patient education, may help minimize excess opioid prescribing while still achieving adequate pain control.
- 26 December 2024
- Published by Springer Nature in Hernia
- Vol. 29 (1) , 1-9
Characterizing patterns of opioid prescribing after outpatient ventral hernia repair with mesh
Purpose Despite efforts to minimize opioid prescribing, outpatient ventral hernia repair (VHR) with mesh remains notoriously painful, often requiring postoperative opioid analgesia. Here, we aim to characterize patterns of opioid prescribing for the heterogenous group of patients and procedures that comprise mesh-based, outpatient VHR. Methods The Abdominal Core Health Quality Collaborative registry was queried for patients undergoing VHR with mesh who were discharged the same or next day between January 2019 to October 2023. Procedures were broadly classified by approach and mesh location: open, minimally-invasive with intraperitoneal mesh (MIP), and minimally-invasive with retromuscular or preperitoneal mesh (MRPP). Surgeon-reported opioid prescription quantity and patient-reported 30-day consumption data were reviewed. Results Of 2,795 patients who met inclusion criteria (46.1% open, 22.7% MIP, 31.2% MRPP), approximately 80% of patients consumed ≤ 10 tablets of opioid pain medication (open 87.7%, MIP 78.4%, MRPP 84.2%). For patients who were prescribed ≤ 10 tablets, the median number of unconsumed tablets was 5 (IQR 0–8). For patients who were prescribed > 10 tablets, the median number of unconsumed tablets was 10 or more (open 10 [IQR 2–16], MIP 10 [IQR 2–18], MRPP 12 [IQR 5–16]). The number of tablets consumed was positively correlated with the number of tablets prescribed (Kendall's rank correlation = 0.232, p < 0.001). Conclusion Regardless of technique, for outpatient VHR with mesh, the fewer opioid tablets prescribed, the fewer tablets patients consumed. Decreasing the prescription quantity to ≤ 10 tablets, coupled with preoperative patient education, may help minimize excess opioid prescribing while still achieving adequate pain control.
- Top Cited PapersOpen Access
- 12 September 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (12) , 7466-7474
Open versus robotic retromuscular ventral hernia repair: outcomes of the ORREO prospective randomized controlled trial
Background: Robotic retromuscular ventral hernia repair (rRMVHR) potentially combines the best features of open and minimally invasive VHR: myofascial release with abdominal wall reconstruction (AWR) with the lower wound morbidity of laparoscopic VHR. Proliferation of this technique has outpaced the data supporting this claim. We report 2-year outcomes of the first randomized controlled trial of oRMVHR vs rRMVHR. Methods: Single-center randomized control trial of open vs rRMVHR. 100 patients were randomized (50 open, 50 robotic). We included patients > 18 y/o with hernias 7–15 cm with at least one of the following: diabetes, chronic obstructive pulmonary disease (COPD), body mass index (BMI) ≥ 30, or current smokers. Primary outcome was occurrence of a composite outcome of surgical site infection (SSI), non-seroma surgical site occurrence (SSO), readmission, or hernia recurrence. Secondary outcomes were length of stay, any SSI or SSO, SSI/SSOPI, operative time, patient reported quality of life, and cost. Analysis was performed in an intention-to-treat fashion. Study was funded by a grant from Society of American Gastrointestinal and Endoscopic Surgeons. Results: 90 patients were available for 30-day and 62 for 2-year analysis (rRMVHR = 46 and 32, oRMVHR = 44 and 30). Hernias in the open group were slightly larger (10 vs 8 cm, p = 0.024) and more likely to have prior mesh (36.4 vs 15.2%; p = 0.030), but were similar in length, prior hernia repairs, mesh use, and myofascial release. There was no difference in primary composite outcome between oRMVHR and rRMVHR (20.5 vs 19.6%, p = 1.000). Median length of stay was shorter for rRMVHR (1 vs 2 days; p < 0.001). All patients had significant improvement in quality of life at 1 and 2 years. Other secondary outcomes were similar. Conclusion: There is no difference in a composite outcome including SSI, SSOPI, readmission, and hernia recurrence between open and robotic RMVHR. Graphical
- 12 September 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (12) , 7466-7474
Top Cited PapersOpen AccessOpen versus robotic retromuscular ventral hernia repair: outcomes of the ORREO prospective randomized controlled trial
Background: Robotic retromuscular ventral hernia repair (rRMVHR) potentially combines the best features of open and minimally invasive VHR: myofascial release with abdominal wall reconstruction (AWR) with the lower wound morbidity of laparoscopic VHR. Proliferation of this technique has outpaced the data supporting this claim. We report 2-year outcomes of the first randomized controlled trial of oRMVHR vs rRMVHR. Methods: Single-center randomized control trial of open vs rRMVHR. 100 patients were randomized (50 open, 50 robotic). We included patients > 18 y/o with hernias 7–15 cm with at least one of the following: diabetes, chronic obstructive pulmonary disease (COPD), body mass index (BMI) ≥ 30, or current smokers. Primary outcome was occurrence of a composite outcome of surgical site infection (SSI), non-seroma surgical site occurrence (SSO), readmission, or hernia recurrence. Secondary outcomes were length of stay, any SSI or SSO, SSI/SSOPI, operative time, patient reported quality of life, and cost. Analysis was performed in an intention-to-treat fashion. Study was funded by a grant from Society of American Gastrointestinal and Endoscopic Surgeons. Results: 90 patients were available for 30-day and 62 for 2-year analysis (rRMVHR = 46 and 32, oRMVHR = 44 and 30). Hernias in the open group were slightly larger (10 vs 8 cm, p = 0.024) and more likely to have prior mesh (36.4 vs 15.2%; p = 0.030), but were similar in length, prior hernia repairs, mesh use, and myofascial release. There was no difference in primary composite outcome between oRMVHR and rRMVHR (20.5 vs 19.6%, p = 1.000). Median length of stay was shorter for rRMVHR (1 vs 2 days; p < 0.001). All patients had significant improvement in quality of life at 1 and 2 years. Other secondary outcomes were similar. Conclusion: There is no difference in a composite outcome including SSI, SSOPI, readmission, and hernia recurrence between open and robotic RMVHR. Graphical
- 18 July 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 236, 115856
Effect of antiplatelet and anticoagulant therapy on bleeding complications following ventral hernia repair: An ACHQC analysis
- 18 July 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 236, 115856
Effect of antiplatelet and anticoagulant therapy on bleeding complications following ventral hernia repair: An ACHQC analysis
- 14 July 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 238, 115846
Continuing home opioid dose in chronic opioid users reduces total opioid use after ventral hernia repair
- 14 July 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 238, 115846
Continuing home opioid dose in chronic opioid users reduces total opioid use after ventral hernia repair
- 5 January 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 232, 68-74
Reducing the incidence of surgical site infection after ventral hernia repair: Outcomes from the RINSE randomized control trial
- 5 January 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 232, 68-74
Reducing the incidence of surgical site infection after ventral hernia repair: Outcomes from the RINSE randomized control trial
- 4 August 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 226 (6) , 896-900
Outcomes of subsequent abdominal operations after an initial ventral hernia repair
- 4 August 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 226 (6) , 896-900
Outcomes of subsequent abdominal operations after an initial ventral hernia repair
- 17 July 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 226 (6) , 858-863
Impact of methocarbamol on opioid use after ventral incisional hernia repair
- 17 July 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 226 (6) , 858-863
Impact of methocarbamol on opioid use after ventral incisional hernia repair